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ABSTRACT

Introduction: The use of multi-ingredient pre-workout supplements has been steadily on
the rise in the fitness industries. Companies make claims about improvements in
performance both physically and cognitively for users but seldom provide research to
back up the claims made about the ingredients or dosages. Purpose: To examine the
effects of Huperzine-A and Alpha-GPC on short term memory and anaerobic power
output, post exhaustion compared to caffeine and placebo in healthy college age students.
Methods: The study was conducted as a double blind, placebo controlled, randomized
design on 62 healthy adults (N=62 height 68.4 ± 3.5 in., weight 78.5 ± 15.1 kg.). The
wash out period was a minimum of 48 hours after completion of the familiarization.
Subjects reported to the exercise physiology lab thirty minutes before testing began and
consumed either a caffeine, Alpha-GPC and Hup-A, or placebo solution. After the thirtyminute digestion period subjects performed one computer-based short-term memory test,
and a thirty-second Wingate anaerobic power test. Subjects then performed an exhaustion
protocol before repeating the memory and power test. Once all testing was completed
subjects returned between 2 and 14 days after the last test and repeat the protocol. A
power analysis was run using G* Power software 3.1.9.2 based from Zeigenfuss et al.,
(2008). The percent change between pre and post was compared across visits using
ANOVA with repeated measures. Significance was found with an Alpha level P ≤ 0.05
with Tukey Post Hoc analysis will be used to determine pairwise comparisons. All stats
were run on IBM SPSS 23. Results: The ANOVA with repeated measures and Tukey
Post Hoc analysis found there was no significant difference in performance pre to post,
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between groups, or factoring the percent change pre to post. Conclusion: This result
suggests there is no physical or mental benefit acutely dosing 600 mg. of Alpha-GPC and
200 mcg. of Huperzine-A in healthy recreationally active adults. This was the first study
to look at the two in combination so, the finding is neither supported nor opposed to the
current body of research. The finding does oppose the logic some supplement companies
have been using to justify their sales tactics. Future research should investigate the effects
of a loading period on physical and mental performance.
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Chapter 1

Introduction

Background
The use of supplements in fitness communities has been on the rise for nearly
the last two decades (Dickinson, Blatman, El-Dash, & Franco, 2014). These
supplements include but are not limited to Protein shakes, Meal replacement shakes,
multi-vitamins, post- workout recovery shakes, nootropics (cognitive enhancers), and
Pre-workouts. Many of these supplements include a long list of ingredients that claim to
increase bioavailability of the substrate, cause a synergistic effect on the recovery
process, increase the palatability upon ingestion, increase duration of workout and
workload ability, or increase mental clarity and focus. Many of the claims about
increased protein consumption post workout are well researched and backed by
evidence, the same is not true for many pre-workout ingredient claims (Jeukendrup, &
Gleeson, 2010)
Many different multi-ingredient pre-workout supplements make the same claim
about being able to increase your strength, focus, workout intensity, and duration but
very few have any empirical evidence to back up the claims made. One major issue with
a large portion of these supplements is they may include some ingredients that do have
some advantageous effects, but the amount is not enough to elicit the desired effect
typically seen as “Proprietary Blends”. One common example is pre-workouts
containing caffeine, this is a widely researched supplement that has been found to
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increase aerobic performance. Supplement companies are highly aware of this claim
and include 200 milligrams of caffeine and stake the claim “workout harder for longer”.
This would be true if the person taking the supplement was 40 kg (88 pounds) because
research shows that to increase aerobic performance with caffeine the ratio must be 5
milligrams per kilogram of body mass (Pasman, Van Baak, Jeukendrup, & De Haan,
1995). So, for the average sized adult, this dose would have little to no effect on
performance. This is one of the most frequently consumed drugs in the world and is
found in a wide variety of drinks and foods (Gilbert, 1984). This makes caffeine and
excellent product to compare when examining the potential benefits of a new
supplement. Caffeine in the correct dose has been shown to be effective in physical and
mental performance (Ganio, Klau, Casa, Armstrong, & Maresh, 2009, Astorino, &
Roberson, 2010), but the mechanisms in which caffeine affects performance is still
unknown and highly speculated (Jeukendrup & Gleeson, 2010). The mechanism of
action in caffeine is highly debated so, that may lead investigators to explore
supplements that act on systems they understand, such as the cholinergic systems. The
use of choline derived supplements has recently sparked the interests of performance
researchers because of its role in acetylcholine synthesis, which plays an extremely
important role in muscle contraction and the synaptic functions.
The manipulation of free choline in the body through ingestion of choline
derivatives may prove to be advantageous in physical performance and cognitive
capability. Alpha-glycerophosphocholine (Alpha-GPC) is a semi-synthetic derivative of
lecithin that acts by releasing free choline, so it can be synthesized into acetylcholine
(ACH) and phosphatidylcholine for biosynthesis in the brain (Gatti, Barzaghi, Acuto,
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Abbiati, Fossati, & Perucca, 1992, Brownawell, 2010). Many studies have shown the
efficacy of Alpha-GPC in decreasing the cognitive decline in patients with Alzheimer’s
disease and dementia (Traini, Bramanti, & Amenta, 2013), but few studies have
investigated its ergogenic effects in exercise performance. Another supplement that has
recently become a point of interest is Huperzine-A (Hup-A) an ancient Chinese herb
from the herb Huperzia Serrata (Wang, Yan, & Tang, 2006).
Hup-A is a selective, reversible, and potent acetylcholinesterase inhibitor
(Wang, et al., 2006). Acetylcholinesterase (ACHe) is the enzyme responsible for the
break-down of ACH in the pre and post synaptic cleft of the neuromuscular and
intraneuronal synaptic clefts. Once ACH is broken down by ACHe it is returned to the
presynaptic axon to be synthesized into ACH (Widmaier, Raff, Strang, 2004). Hup-A,
like Alpha-GPC, was originally used in research on patients with neurodegenerative
diseases and showed marked improvements on cognition in experimental trails (Wang,
2006). There is no current research on the effects of Hup-A in physical performance,
but it has been shown to effectively inhibit ACHe in healthy adults (Morasch, Aaron,
Moon, & Gordon, 2015). ACHe is the enzyme that breaks down ACH at the postsynaptic receptors, if this enzyme can be inhibited it may increase the firing rate of the
synapse. The same principle may apply in the use of Hup-A to manipulate the process
by which ACH is cycled in the neuromuscular junctions. The potential for increased
cognitive functioning and physical performance when properly stacking Alpha-GPC
and Hup-A may prove to be an effective replacement for caffeine in pre-workout
supplements.
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The current study proposed to examine the effectiveness of acute
supplementation of Hup-A and Alpha-GPC, on cognitive performance and physical
performance in healthy adults before and after an exhaustive protocol, compared to
Caffeine and Placebo.

Limitations, Delimitations, Assumptions
The current limitations, delimitations, and assumptions are made from the pilot
testing performed prior to the official data collection. As data collection and testing
proceeds researchers may find some limiting factors in the true experimental design that
cannot be controlled for. These limitations may include but are not limited to
controlling for subject eating habits. Subjects will be asked to refrain from any heavy
meals prior to testing because they may lead to potential issues with proper absorption
of the supplements. Also, a heavy meal may reduce subject performance during the
physical performance skewing test results. Problems with cramping, gut pain, or even
vomiting may occur if over feeding occurs prior to the testing battery. Investigators will
be sure to ask subjects when their last meal was and make sure they will not have any
gastrointestinal issues during testing. If the subject feels they cannot perform their best,
testing will be rescheduled. Consumption of caffeine prior to testing will also be
discouraged in order to avoid a stacking effect or a potential overdose or synergistic
effects from the combination of treatment and what subjects may potentially consumed
on their own.
Subjects will be asked to refrain from any intense workouts 24 hours prior to
testing as to avoid a premature fatiguing effect. Researchers will diligently question
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subjects to make sure there was no previous intense exercise they may skew
performance results.
Potential limitations may also include caffeine sensitivities in subjects that are
non-users, or potential side effects from the dosing of Hup-A. Mild, occasional, side
effects have been reported with oral supplementation of Hup-A (nausea, vomiting,
diarrhea). These potential side effects will result in an immediate discontinuation of
testing with that subject. This study will also be limited by the equipment technology
and size of the lab hosting the testing protocol.
Delimitations of the study will be proper dose timing of 30 minutes which will
begin once the subject has ingested the full treatment and time will be kept by the
researchers on cite. Physical performance will be collected via a single 30 second
Wingate using a Monarch cycle ergometer, which has been shown to be a reliable and
valid means to measure anaerobic power output. A standardized post exhaustive
protocol recovery time of 5 minutes. Time will begin immediately once the subject
finished the protocol completely. Subjects will be placed on a computer with noise
canceling headphones/earplugs to ensure they are not distracted by outside influences
when short term memory. Short term memory test will be simple and thoroughly
explained by researchers and warm up rounds will be provided before each test to
ensure instructions are understood.
Assumptions of this study are that subjects will come into each testing session
well rested and will give best efforts in all trials (Investigators will record hours of sleep
subjects had the previous night). It is also assumed that all subjects will be forth coming
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with any injuries that may hinder performance during the Wingate, as well as any
mental clarity issues that may impede cognitive functioning during the trials.

Problem statement
Supplement companies put arbitrary amounts of different ingredients and make
claims about the effects their blend being advantageous for both physical and cognitive
performance. Many supplements in these products have no research-based evidence that
suggests they will cause an increase in performance and in some cases, these products
will contain an ingredient that has been shown to have beneficial effects, but it is an
insufficient dose. Alpha-GPC and Hup-A have been shown to improve cognitive
performance and physical performance.
The purpose of this study is to test the effectiveness of Alpha-GPC and Hup-A
in a stack supplement on improving cognitive and physical performance post exhaustion
compared to placebo and caffeine healthy college aged adults. The approach
investigators will use is an experimental double-blind placebo-controlled protocol.

Hypothesis
Hypothesis 1 – It was hypothesized that 600 mg of Alpha-GPC and 200 mcg of
Hup-A would improve anaerobic power output and short-term memory pre and post an
exhaustive protocol, in healthy college aged students compared to 5 mg/kg of caffeine
and placebo.
Hypothesis 2 – It was hypothesized that 600 mg of Alpha-GPC and 200 mcg of
Hup-A would improve anaerobic power output but not short-term memory pre and post

6

exhaustive protocol, in healthy college aged students compared to 5 mg/kg of caffeine
and placebo.
Hypothesis 3 – It was hypothesized that 600 mg of Alpha-GPC and 200 mcg of
Hup-A would improve short term memory but not anaerobic power output pre and post
an exhaustive protocol, in healthy college aged students compared to 5 mg/kg of
caffeine and placebo.
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Chapter 2

Review of Literature

Background
Multi-ingredient pre-workouts have become popularized amongst fitness
enthusiast and athletes at all levels in the health and wellness industry (Dickinson,
Blatman, El-Dash, & Franco, 2014). Each specific supplement in the recipe having its
own claim to how it increases performance, most of which make claims regarding
increases performance, in strength, power, fatigue resistance, and better focus. In
theory, these combinations of supplements may prove to be advantageous for users but,
there is very little research as evidence to support the claims made. A. R. Jagim and
associates published one of few studies analyzing the effects of Multi-Ingredient PreWorkout Supplements (MIPS) against placebo (Jagim, Jones, Wright, Antoine, C.
Kovacs, & Oliver, 2016). One issue with this method is it leaves much room for
questions about which supplement or combination was responsible for the desired
effects observed in the research, three main supplements used in the MIPS were
caffeine, Alpha-Glycerolphosphocholine (Alpha-GPC), and Huperzine-A (Hup-A).
Caffeine is a widely used substance that has been found to be efficacious for physical
and mental performance tasks. Multiple systematic reviews on the effects of caffeine on
sports performance have been published due to its wide use in athletics and ability to
improve cognitive performance (Ganio, Klau, Casa, Armstrong, & Maresh, 2009,
Astorino, & Roberson, 2010).
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Alpha-GPC is a relatively new supplement in the performance world. There are
very few studies done on the effectiveness of alpha-GPC in peak performance but
author T. Ziegenfuss suggests it may be effective in increasing peak power, anaerobic
power, and human growth hormone levels (Ziegenfuss, Landis, & Hofheins, 2008).
Hup-A comes from the naturally occurring Chinese herb and is a reversible
cholinesterase inhibitor and comes from Huperzia serrata (Rathee, Chaudhary, Rathee,
& Rathee, 2008). This herb has been shown in some research to be an effective memory
booster in monkeys (Ye, Cai, Wang, & Tang, 1999), suggesting the possibly of
providing similar effects in humans. Here has been little to no research of the effects of
Hup-A in healthy adults on mental or physical performance. The purpose of this literary
review is to gauge the efficaciousness of Alpha-GPC and Hup-A against caffeine and
their possible uses in mental and physical performance in healthy individuals.

Caffeine
Caffeine is arguably one of the most widely used drugs in the world according to
author R.M. Gilbert, 1984. Caffeine is consumed primarily in the form of coffee 54%,
and tea 43%, but is found in a wide variety of products. Other products with caffeine
include chocolate, chocolate milk, candy bars, hot chocolate, sodas, and even
decaffeinated coffee still contains some caffeine (Gilbert, 1984). In 1996, Author J. J.
Barone reports from the available data that the average consumption in users in the
United States is 4 milligrams per kilogram of bodyweight (mg/kg) (Barone, & Roberts,
1996). For a person of about 200 pounds that means they are taking approximately 365
mg of caffeine a day.
9

Physiological/psychological response to caffeine
Caffeine has been found to have a wide variety of uses in the average person’s
day to day life. Many of the uses for caffeine are beyond the scope of this review. While
there is a plethora of benefits one may receive, some populations experience adverse
health effects like an acute rise in blood pressure at rest (Robertson, Frölich, Carr,
Watson, Hollifield, Shand, & Oates, 1978). Robertson, D. et al., (1978) reported a rise
in mean blood pressure of 10/14 (systolic/diastolic) one hour after a 250 mg dose. If
chronic use were to become chronically high blood pressure this could pose long term
health problems. On the contrary, a meta-analysis on of coffee consumption showed
that 4 cups a day can decrease chances of heart attack, but 10 cups a will return the risk
back to baseline (Mostofsky, Rice, Levitan, & Mittleman, 2012). Evidence suggests that
there are some potential benefits with caffeine consumption, and some slight
complications, which both are dependent on dose and the tolerance of the individual.
The effects on the physiology are easier to track because investigators can quantify the
responses simply and uniformly, psychological responses are reasonably less straight
forward. These responses may pose and issue in caffeine intolerant populations through
increased levels of perceived anxiety and brain lactate levels, these increases were
found after subjects were given a dose of 10mg/kg of caffeine (Dager, Layton, Strauss,
Richards, Heide, Friedman, ... & Posse, 1999). Brain lactate levels were found not to be
causational to increased anxiety levels by investigators. Hormonal response may be one
of the factors leading to the perceived anxiety according to Lane J. D. et al., (1990). A
robust increase in plasma epinephrine and cortisol at a dose of 3.5 mg/kg in both non
and chronic users, as well as increases in blood pressure and heart rate (Lane, Adcock,
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Williams, & Kuhn, 1990). This finding is hard to categorize as either psychological or
physiological because it is sensationalized in both areas simultaneously. For a caffeine
user with a relatively high tolerance, they may not experience any of the adverse effects
of the high doses that come in some pre-workout supplements. But, for some
individuals the side effects caused by high caffeine doses may out-weigh the benefits.
For caffeine intolerant athletes and exercise enthusiasts use of cholinergic supplements
may prove to be advantageous.
Aerobic physical performance
There are some clear disadvantages to acute and habitual use of caffeine but,
there are some accompanying advantages to supplementation as well. One study
provided evidence that caffeine can increase time to exhaustion in cyclists (Costill,
Dalsky, & Fink, 1978). Researchers had experienced cyclists’ bike until exhaustion on
stationary bicycle ergometer at 80% of their VO2 max. One trail was placebo controlled
with decaffeinated coffee, but the other trial was performed with regular coffee
containing 330mg of caffeine, results showed that the caffeine trail increased the
average time to exhaustion to 90 minutes, compared to 75 minutes in placebo. Upon
Further investigation of supplementation for performance, researchers have found the
ergogenic effects of caffeine on endurance performance are dose dependent. In a review
of caffeine by authors A. Jeukendrup and M. Gleeson they suggest that endurance
performance response is dependent on dose relative to body weight. A study by
researcher W. J. Pasman compared endurance performance time by giving subjects 0, 5,
9, and 13 mg/kg of caffeine and analyzing the difference in time to exhaustion. They
found that each dose besides 0 mg/kg had a marked effect increasing performance but
11

no significant increases after 5 mg/kg (Pasman, Van Baak, Jeukendrup, & De Haan,
1995). The use of caffeine has shown to have an advantageous effect on aerobic
performance, but there is little evidence suggesting the same for anaerobic performance.
Anaerobic physical performance
Once researchers established that the use of caffeine in aerobic performance
attention turn toward it’s potential to enhance anaerobic performance. this studies
specifically focused on trained vs untrained populations and a variety of sport-specific
and non-specific movements. At a dose of 7 mg/kg trained athletes did not see an
increase in performance during 3, l-minute bouts on a cycle ergometer (Vanakoski,
Kosunen, Meririnne, & Seppala, 1998). While this study’s focus was to test the effects
of creatine consumption on athletes, researchers did well in testing the effect of caffeine
on anaerobic power as well. This study suggests caffeine has little effects on anaerobic
power output during a 30 second Wingate on a cycle ergometer. Because the Wingate is
a non-sport specific test, researchers thought to look at the effects of caffeine on a sport
specific sprint. Researchers J.K.Davis and M. J. Green (2009) report in a review of
caffeine on anaerobic power that caffeine had no marked effect on sprints for power or
speed (J. Davis and M. Green, 2009). Similar results were found in a study testing
division 1 football players during 6, 35-meter sprints. The caffeine taurine mixture
administered found no improvements on power output compared to placebo (Gwacham
& Wagner, 2012). Caffeine has shown marked effects in research on aerobic
performance of athletes but, as previously stated there is little evidence to suggest that it
has any advantageous effects on anaerobic power output in trained or untrained
populations.
12

Cognitive Effects
It is widely accepted that caffeine increases performance in an academic setting,
but there is limited research for that specific area to support the claim. A large study
(N=1604) compared the effect of caffeine on introverts versus extroverts. Researchers
found large doses of caffeine increased intelligence performance tests in extroverts but
not introverts (Gupta, 1988). Similar effects on working memory were found in
extroverts at a dose of 200 mg (Smillie, & Gökçen, 2010). Caffeine’s effect of
individuals is largely found to be dose dependent and there is a threshold that can cause
issues in memory with non-caffeine users. A dose of 450 mg of caffeine was found to
decrease performance on memory tasks in non-users but, this high dosage increased
performance in reaction time testing (Childs & De Wit, 2006). These results suggest
that there is a bell curve effect on the use of caffeine in the ability to increase cognitive
performance in individuals, optimal dosing varies based on previous exposure
(tolerance) and the weight of the user.
Mechanism of action
The mechanism of action in which caffeine effects performance is highly
debated but there are several theories on how it works. Authors Jeunkendrup and
Gleeson provide several theories on these mechanisms of action. One, is due to
caffeine’s ability to stimulate fat oxidation (lipolysis) muscles can spare their glycogen
stores more effectively, this in-turn provides longer lasting energy during endurance
performance. Another theory is “Possibilities include the handling of ions, inhibition of
phosphodiesterase leading to an increased concentration of 3’,5 -cyclic adenosine
monophosphate (cAMP).” This theory is based on the idea that enzyme manipulation by
13

caffeine changes the handling of ions that are used in exercise performance. One
possible theory is the effect caffeine has on calcium, increasing calcium release from
the sarcoplasmic reticulum has increases muscle cell excitability. Therefore, one might
see an increase in ability to contract muscle as well as, increased time of ability to
contract. Lastly, caffeine is a central nervous system stimulant that has a marked effect
on “…perceptions of effort or affects the signal transduction from the brain to the
neuromuscular junction.” If caffeine can manipulate the ability to increase synaptic
connections at the neuromuscular junctions then that of contractions would increase and
possibly last longer (Jeukendrup and Gleeson, 2010 p. 269) (Table 1).
Table 1
Caffeine Doses and Effects
Use
Dosage
Aerobic
330 mg

Effective
˄ time to
fatigue

Source
Costill et al., 1978,

5 mg/kg
7 mg/kg
200 mg

Pasman et al., 1995
Vanakoski et al., 1998
Smillie, 2010

Physiological

NO
˄ extrovert
memory
250 mg- 3.5 mg/kg Robust effect

Psychological

10 mg/kg

Robertson et al., 1978,
Lane et al., 1990
Dager et al., 1999

Anaerobic
Cognitive

Yes
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Importance of Choline
The use of Acetylcholine (ACH) in cell function, muscle contraction and
synaptic function, is well documented. Being the first neurotransmitter to be discovered
in 1921 by German biologist Otto Loewi (Boeree, 2003) researcher have and in-depth
understanding of its use in the body and where it is synthesized from. ACH is derived
from the substrate choline, making choline essential to releasing action potentials all
through the body, especially in muscle contraction. Authors Jeukendrup and Gleeson
describe its connection very well “Acetylcholine transmits the electrical potential from
neuron to muscle cell, leading to the calcium release from the sarcoplasmic reticulum
and muscle contraction…, The precursor of acetylcholine is choline, a normal
component of the human diet” (Jeukendrup and Gleeson, 2010). The abundance of
choline in one’s diet is important because of its lipotropic effects in the liver, choline
helps prevent lipid accumulation on the hepatocytes (Best and Huntsmen, 1932). Until
Best and Huntsman began their research initially looking at insulin but, discovered that
choline inhibits fatty liver accumulation. Before this research, choline was under
appreciated as a micronutrient essential to one’s health. Thanks to the wide variety of
foods that contain choline mostly meats, legumes, and dairy products there is a low
chance one would find themselves in a deficit while eating a well-balanced diet.
Because of the crucial role ACH plays in the neuromuscular junction, this has led
researchers to use concentrated forms of choline for supplementation. These
concentrated forms of choline are broken down more easily into phosphorylcholine
after ingestion than regular dietary choline. Phosphorylcholine is the metabolically
active form of choline, it is used in the synaptic cleft through the entire central nervous
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system (De Ferra, Hagerman, Purpura, Jaeger, Hagerman, & Zenoni, 2016). Author De
Ferra elaborates well on the function of phosphorylcholine stating “Phosphorylcholine
migrates to the synaptic nerve endings found throughout the entire central nervous
system, and in turn increases ACH synthesis and release. ACH is a vastly important
neurotransmitter present in both brain and muscle tissue. In the brain, ACH plays a key
role in basically every cognitive function, while in muscle, it is vitally involved in
muscle contraction, as it is the major neuro-transmitter involved in regulating
physiological response to exercise.”
Some examples of choline concentrates are Citicoline (CDP-choline), this
supplement has shown efficacy in preventing the cognitive decline associated with post
stroke symptoms (Alvarez-Sabin, 2011). This form of choline concentrate demonstrates
very important neuroprotective properties that may be useful in increasing cognitive
performance in healthy individuals. These implications suggest that choline derived
supplements are not only functional in physical performance, researchers may find use
for increased cognitive performance as well. Another form of choline concentrate that is
proving to be advantageous in mental, physical and physiological performance is
Alpha-glycerophosphocholine.
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Alpha-Glycerophosphocholine
Alpha-glycerophosphocholine (Alpha-GPC) is a natural derivative of the
substrate choline, which is used in the body to synthesize ACH, a vastly important
neurotransmitter. Alpha-GPC was developed to act by releasing free choline that in-turn
will increase ACH and phosphatidylcholine biosynthesis in the brain (Gatti, Barzaghi,
Acuto, Abbiati, Fossati, & Perucca, 1992). Brownawell et al. (2011) describes it as a
“semi-synthetic derivative of lecithin. Following oral administration, it is converted to
phosphorylcholine, a metabolically active form of choline able to reach cholinergic
synaptic endings where it increases acetylcholine synthesis and release (Brownawell et.
al., 2011, Lopez et. al., 1991, Trabucchi et al., 1986, Abbiati et al., 1991)”. This suggest
that ingestion of Alpha-GPC could lead to an increase in plasma choline levels.
Effects on Physical Performance
Alpha- GPC has been hypothesized to increase physical performance in power,
strength, and aerobic performance, one study found an interesting result on the post
work-out growth hormone secretion and bench press in males. Researchers Tim
Ziegenfuss, Jamie Landis, and Jennifer Hofheins tested the Alpha-GPC on seven
resistance trained men to see its effect on explosive performance and growth hormone
levels. Subjects were given 600 mg of Alpha-GPC or placebo 90 minutes before
exercise, then performed an exhaustive squat protocol. After thirty minutes of rest they
performed a bench protocol to assess peak power, serum samples to assess growth
hormone secretion were taken immediately, fifteen minutes, thirty minutes, and every
thirty minutes until the two-hour mark. Researchers found that peak growth hormone
secretion increased 44-fold in the alpha-GPC trails, and bench press force increased by
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fourteen percent. Increased bench press power was trending, as well as, lower post
exercise respiratory exchange rate (Ziegenfuss, Landis, & Hofheins, 2008).
Investigators conclude that 600 Mg of Alpha-GPC increases bench press force and
growth hormone secretion and suggest future research be directed toward its effects on
binding proteins when coupled with resistance training, but the lowering of respiratory
exchange ratio post exercise has interesting implications to future research as well.
From the result of this study there is reason to believe that Alpha-GPC may provide and
ergogenic effect on endurance performance and muscle contractile time. Some
researchers have taken interest in loading Alpha-GPC and its unique effects on force
production. Bellar, D. et al., (2015) investigated isometric strength after loading AlphaGPC compared to placebo. Research was performed using 13 healthy male college
students, they were provided with either 600 mg of Alpha-GPC to take daily or a
placebo after baseline measurements were taken. After a 6-day loading phase of either
Alpha-GPC or placebo subjects performed an isometric mid-thigh rack pull and
isometric pushup against force plates and force production was measured in both.
Researchers found significant increase in the mid-thigh pull strength and a trend toward
significant change in the push-up. Bellar reports “Magnitude based inferences suggest
that the A-GPC was 68.3% likely beneficial for increasing upper body isometric force
and 86.5% likely beneficial for increasing lower body isometric force production.”
(Bellar, LeBlanc, & Campbell, 2015). Another study examined Alpha-GPC’s effects on
counter movement jump height, 40-yard dash time, and Wingate anaerobic power
output compared to placebo. Subjects were given 300 mg of Alpha-GPC administered
with a sports drink 1 hour before testing. Results found a significant improvement in the
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counter movement jump compare to placebo but no improvement in the Wingate or 40yard dash (Rickard, 2017). Research examining the effects of Alpha-GPC on physical
performance are sparse and should be further pursued.
Effects on cognition and mood
There is evidence to support the claim that Alpha-GPC may also increase
cognitive performance (Traini, Bramanti, & Amenta, 2013). Traini found that the use of
cholinergic precursors and acetylcholinesterase inhibitors can improve memory and
attention in patients with dementia. Due to the vast use of acetylcholine throughout the
central nervous system and its importance in the neuromuscular junction use for AlphaGPC to improve reaction time testing in healthy adults. Researchers found that
“CRAM” a supplement containing Alpha-GPC (150 mg), choline bitartrate (125 mg),
phosphatidylserine (50 mg), niacin (vitamin B3; 30 mg), pyridoxine HCl (vitamin B6;
30 mg), methylcobalamin (vitamin B12; 0.06 mg), folic acid (4 mg), L-tyrosine (500
mg), anhydrous caffeine (60 mg), acetyl-L-carnitine (500 mg), and naringin (20 mg),
maintained reaction times pre and post exhaustive protocol (Hoffman, Ratamess, N.
Gonzalez, Beller, Hoffman, Olson, & Jäger, 2010). As previously stated,
phosphatidylcholine is the metabolically active form of choline which can be used in
the neuromuscular junctions to synthesize acetylcholine, an important neurotransmitter
for proper cell function and specifically for muscle contraction (De Ferra, 2016). In the
research performed by Hoffman et al. (2010) subjects were given either placebo of
CRAM supplement in the initial testing once given time to relax and digest they filled
put a survey fatigue, focus, alertness and energy. Then, subjects performed a reaction
time test and an exhaustive protocol followed by another survey and reaction test.
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Hoffman, J. R. et al., (2010) reports that acute supplementation of CRAM has shown
that subjects maintain feelings of focus and alertness but also maintain reaction times
pre and post (Hoffman et al., 2010). These results may suggest the increased availability
of phosphatidylcholine can lead to better performance in cognitive tasks. One issue with
this study is that it was a multi ingredient supplement so there may be some
compounding factors contributing the results found. Performance supplements such as
caffeine are dose dependent (Pasman et al., 1995), dosing is typically measured as
milligram per kilogram of body weight (mg/kg). Further research on the effects of
Alpha-GPC relative to body size is needed, it is widely accepted that the consumption
of Alpha-GPC at relatively high doses is safe for oral consumption (Bronawell, 2011).
Safety of ingestion
Researchers must be careful when testing relatively high doses in patients
because of potential toxicity, Alpha-GPC has been found to be found and is widely
considered to be safe for consumption in moderate to high doses. The oral ingestion
toxicity rate has been found to be very high and doses in rats had to be up to 10,000
mg/kg to exhibit toxic effects or death (Brownawell, 2011). The research suggests that
Alpha-GPC is safe for consumption at relatively high doses (Table 2).
Table 2
Alpha-GPC Dosing and Effects
Use
Dose
Exercise
600 mg
performance
600 mg
Cognitive
performance

150 mg

Timing
90 minutes

Effective
↑ LE Peak, ↑
HGH

6-day loading

↑ UE/LE
isometric
strength
↑ mood and
attention?

20 minutes

20

Source
Ziegenfuss et
al., 2008
Bellar et al.,
2015
Hoffman et al.,
2010

Huperzine-A
Huperzine-A (Hup-A) is a novel alkaloid that comes from the Chinese herb
Huperzia serrata, and is a selective, reversable and potent acetylcholinesterase inhibitor
(Wang, Yan, & Tang, 2006). Acetylcholinesterase (ACHe) plays an important role at
the neuromuscular junction, where acetylcholine (ACH) is released in the synaptic cleft
it binds to the postsynaptic ACH receptors. Once the action potential is released from
the motor endplate the enzyme ACHe breaks down the built up ACH into choline and
acetate. After the breakdown, choline is returned to the presynaptic axon where it is
reused for the synthesis of new acetylcholine (Widmaier, Raff, Strang, 2004). This wellestablished breakdown gives useful insight to how ACH and ACHe are used in the
neuromuscular junction, but as previously mentioned, these compounds are used
throughout the entire nervous system. The series of events are similar but there are
some slight variations in the intraneuronal synapses versus the neuromuscular junctions.
In the nervous system the synapses are referred to as cholinergic, action potentials
arrive at preganglionic axon releasing ACH into the “intra-axonal storage site” once the
ACH crosses the cleft it causes the postsynaptic potential to travel down the ganglionic
fiber, this is where ACHe begins to break down ACH on the post synaptic membrane
(Koelle, 1962).
Effects on cognition
There are many similarities between the two systems, both of which are
affected by the manipulation of ACH and ACHe. Hup-A has been found to improve
cognitive deficits in the elderly population. It is used for treatments in patients with
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“Alzheimer disease and vascular dementia, with minimal peripheral cholinergic side
effects and no unexpected toxicity.” (Wang, 2006).
Animals
One study examined the effects of Hup-A on monkeys with scopolamine
induced memory deficits (Ye, Cai, Wang, & Tang, 1999). In this study 8 monkeys, 4
young and 4 old, were tested using a delayed response task. They were shown two food
bowls one which was filled, then they were separated from the bowls by a screen for
increasingly longer periods of time. The monkeys were intravenously given doses of
scopolamine to significantly decrease choice accuracy, and then given Hup-A or a
placebo in the same manner, both were dosed according to body weight. They found
that Hup-A increased delayed response accuracy in young monkeys given scopolamine
with peak effect being a dose of .1 mg/kg with a decrease in effectiveness in .2 mg/kg.
No negative side effects were reported at the administered doses and suggest optimal
dosing for advantageous effects.
Humans
In one study on healthy adults, researchers tested the effect of 100 and 200
micrograms of Hup-A on acetylcholinesterase (ACHe) and butyrylcholinesterase
(BCHe) and neurobehavioral performance. Both doses of Hup-A significantly inhibited
the release of ACHe but not BCHe, researchers speculate this is due to the selective
property of Hup-A. No changes were found in the neurobehavioral performance
(Morasch, Aaron, Moon, & Gordon, 2015). Morasch et al. (2015) states that that doseresponse studies should be done to determine the neuroprotective properties of Hup-A
and other cholinesterase inhibitors.
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Safety
There have been few trails using Hup-A in healthy adults but there was little to
no negative side effects associated in this group at dosages of 100- 200 mcg (Morasch
et al., 2015). Most of the human clinical trials have been done in patient populations
with Alzheimer’s disease to enhance cognitive ability and alleviate symptoms
associated with this neurodegenerative disease. In one meta-analysis Wang et al. (2009),
focuses on the efficacy and safety of Hup-A specifically in patients with Alzheimer’s
disease. Authors examined 4 large clinical studies where primary outcomes were
focused on mini-mental state examinations and activities of daily living (Wang, Wang,
Wei, Song, Zhang, & Chen, 2009). The meta-analysis revealed there were no adverse
effects on vital signs, blood work, or electrocardiogram readings. Effects were mild to
moderate in the worst cases scenarios and typically diminished with time, side effects
included nausea, vomiting, and diarrhea; investigators report it was more likely to
happen with Hup-A treatment groups than placebo, but it was not statistically
significant. The recommended doses were between 300-500 mcg a day in groups with
Alzheimer’s disease, western countries had a growing interest in the use of Hup-A as a
cognitive enhancer in populations in the normal cognitive range and in the United States
there were a few supplements that sold it in 100 mcg doses. The statistics from Wang et
al. suggest that high doses of Hup-A are required to elicit positive effects in populations
with neurodegenerative diseases.
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Physical performance
Currently there is no research comparing the effects of Hup-A against placebo or
any other supplement to examine its effects on performance or ability to recover from
strenuous repeated bouts of exercise (Table 3).
Table 3
Hup-A Dosing and Effects
Use
Dose
Healthy adults’
100-200 mcg
cognitive performance
Adults with
300-500 mcg
neurodegenerative
disease
Animal trials
.1 mg/kg
Physical performance

N/A
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Effective
No

Source
Morasch, K. C. et al., 2015

˄ cog.
Scores

Wang, B. S. et al., 2009

˅ cog.
Decline

Ye, J. W. et al., 1999

N/A

None

Chapter 3

Methods

Overview
The purpose of this study was to investigate the synergistic effectiveness of 600
mg of Alpha-GPC and 200 mcg of Hup-A against 5 mg/kg of caffeine and placebo, in
increasing anaerobic power output and short-term memory pre and post an exhaustive
protocol, in healthy college aged students. The study was conducted as a double blind,
placebo controlled, randomized cross over design. The wash out period was a minimum
of 48 hours after completion of the testing battery and up to 7 days. Subjects reported to
the exercise physiology lab thirty minutes before testing began and consumed either the
caffeine, Alpha-GPC and Hup-A, or placebo solution. After the thirty-minute digestion
period subjects completed a computer based short term memory test and a thirty-second
Wingate anaerobic power test. After 3-5 minutes of low intensity pedaling, subjects
performed a high intensity training battery and then were given 5 minutes of full
recovery before repeating the first testing battery. Once all testing was completed
subjects returned between two and fourteen days after the last test and repeated the
protocol.
Procedure and instruments
Subjects reported to the Exercise physiology lab for two testing sessions thirtyminutes prior go the beginning of the testing battery. During the first session subjects
were required to fill out the proper IRB approved informed consent and Health history
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questionnaire. Subjects were tested for body composition via bioimpedance
spectroscopy (BIS) on the SOZO (ImpediMed limited Queensland, Australia) for body
fat and lean mass percentage.
In the treatment trials, the subjects were given either solution of 5 mg/kg of
caffeine (PURCAF caffeine by KAGED muscle, Boise, Idaho), 200 mcg of Hup-A
(Huperzine-A by Double wood supplements, Philadelphia, Pennsylvania) and 600 mg
of Alpha-gpc (AlphaSize by Chemi Nutra, Austin, Texas), or a placebo (Karbolyn Fuel
by EFX Sports, San Jose, California) 30 minutes before the testing battery began.
Randomization was based on rolling a dice by a third-party investigator. The dice roles
were assigned to specific treatments by a third-party investigator was responsible for
supplement dosage, but was not involved with data collection to ensure true doubleblind protocol is followed. All treatments were administered with 8 ounces of water,
mixed with 1 standard serving of “Blue Razz Watermelon” (Karbolyn Fuel by EFX
Sports, San Jose, California) carbohydrate supplement to ensure subjects weren’t able to
tell a difference in flavor across sessions. The Alpha-GPC, Hup-A and caffeine were
administered in a white flavorless powder form mixed with the carb supplement for
uniformity across visits.
30 minutes after consumption, subjects began the short-term memory
assessment. Investigators used a computer-based digit span task software to assess short
term memory called a Digit Span memory test performed on PsychoPy by Python
software created by Dr. Donald Varakin (Peirce, & MacAskill, 2018). The test took
subjects roughly 11-13 minutes per session. Subjects were given a verbal explanation of

26

the testing procedure before the start and were allowed 1 trial test. The testing
procedure is as follows;
One number at a time appeared in the center of the testing window for 1 second
with a 1 second delay before the next number appears. Once each number has been
displayed a blue enter bar appeared to cue the subject to enter their response. The goal
was for the subject to enter all the numbers displayed in the order they appeared for
each sequence. The test was divided into 8 parts of 3 number sequences, the first set of
3 had 2 digits, the second 3, the third 4, and increased until the last set contained 10
digits. Scoring was shown as the percent correct of each sequence from the different
sequence lengths. The average percent was calculated from all sequence percentages as
a cumulative score. Once subjects complete the full digit span task, they completed a
Wingate anaerobic power test.
The 30 second Wingate anaerobic power test was performed on a Peak Bike
cycle ergometer (Monark, Ergomedic 894E) where mean, peak, and minimal power
output were recorded. Subjects were given between a 1 minute and 30 second to 5minute warm-up requiring that they stay between 60 and 100 revolutions per-minute
(rpm) before the onset of the test. Once the warm-up was over subjects were instructed
to work up to a maximal sprint, at 120 rpm a weight of 7.5% of their weight in
kilograms dropped and created a constant resistance until the end of the 30 seconds.
Upon completion the investigator released the resistance and subjects were instructed to
continue pedaling for 3 minutes as a cool down.
Peak power output was defined as the most mechanical power output during the
test in watts, mean power was the average observed throughout the duration of the test,
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minimal power was the least amount of mechanical power output during the test, all
values were recorded in watts. Power outputs were calculated in the Monarch analysis
software.
Upon completion of the Wingate anaerobic power test and cool down, subjects
performed an exhaustive protocol. Three simple exercises were chosen to ensure each
subject was able to complete them safely and until they are thoroughly fatigued; pushup, sit-up, and the body weight squat (to the best of their ability). ACSM standards for
proper form in each movement to ensure all subjects are being tested uniformly (Proper
form displayed in figures 1-3). Each exercise was performed for 1 minute as fast as
possible, investigators were watching to ensure correct form is always being used. It is
assumed that subjects gave their best effort to ensure a fatiguing effect. Protocol was
chosen as an adaptation of the exhaustive protocol used by Hoffman et al., (2010). Once
the subject had gone to failure in the exhaustive protocol, they were allowed a 5-7minute break plus up to 6 ounces of water for rehydration (without the threat of stomach
cramping). After the short break subjects will repeat all the testing measurements in the
same order. Both pre-exhaustion and post-exhaustion scores were compared in all 3
supplement trials and compared to baseline (Figures 1 – 3).

Figure 1 Correct sit up form
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Figure 2 Correct squat form

Figure 3 Correct push up form

Data Analysis
Descriptive statistics were reported for demographic variables with means and
standard deviations provided for continuous variables and frequencies and percentages
provided for categorical variables. Normality testing was performed on each variable of
interest using the Shapiro Wilk test. For the cognitive and anaerobic power output
performance comparisons, a sample size of 10-15 per-group was determined as an
effective sample size. Based on the number of groups (3) total number of subjects to
provide 80% power would be 30-45 to detect a difference between visits/groups. Based
on the results of Ziegenfuss et al., (2008), with an average between groups difference
being 875 watts (Group 1, 933 watts. Group two 818 watts), significant differences will
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be found at an alpha level of P ≤ 0.05. Power analysis was run using G* Power software
3.1.9.2 (Heinrich Heine, Universitat Dusseldorf). Data was analyzed in a two-step
process. First, subject’s performance was compared pre to post session to find the
percent change in accuracy in the digit span test and peak power, average power, and
minimum power output during the 30 second Wingate. These percentages were
calculated for each of the subject visits familiarization, Placebo, Caffeine, and HupA/Alpha-GPC (treatment). Paired sample T-tests were ran to normalize data, using IBM
SPSS 23 (Armonk, NY). Second, the changes were compared across groups using a
repeated measures analysis of variance (ANOVA) using the same software as used for
the T-test. All visits were compared across visits for each metric. Significance was set
with an Alpha level of P ≤ 0.05 with Tukey Post Hoc analysis used to determine
pairwise comparisons significant differences.
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Chapter 4

Results

Descriptive statistics
65 healthy adults volunteer to take place in the study, after three subjects were
dropped from testing due to scheduling conflicts during the allotted time frame. 62
(N=62 height 1.74 ± 0.089 m., weight 78.5 ± 15.1 kg.) completed the study and were
used to analyze results. There were two separate sample sizes used to calculate results
from the two-testing metrics. Digit span memory test had a sample size of N=54 and the
Wingate Anaerobic power test had a sample size of N=62. Differences in sample sizes
were due to technical issues with the Lab computer, once the issue was resolved testing
continued as usual. Each subject was randomly assigned to one of the following groups,
Placebo (N=21), Caffeine (N=19), and Alpha-GPC/Huperzine-A (N=22) in Power
output testing. Each group’s results were normalized as a percent of change from pre to
post among the following metrics of measure, Peak power visit 1 and 2 (PPv1 and
PPv2), Average power visit 1 and 2 (APv1 and APv2), and Minimum power visit 1 and
2 (MPv1 and MPv2). Descriptive statistics for the power output percent change are
shown in table 4.
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Table 4
Percent power change descriptive statistics
Metric
Group
Mean ± Std. Dev. Std. Error
PP v1
Placebo
3.07% ± 10.35%
2.26%
Caffeine
8.36% ± 11.90%
2.73%
Treatment 4.15% ± 10.63%
2.27%
PP v2
Placebo
-0.05% ± 9.63%
2.10%
Caffeine
1.98% ± 12.65%
2.90%
Treatment -0.91% ± 13.82%
2.95%
AP v1
Placebo
3.3% ± 8.97%
1.96%
Caffeine
8.49% ± 8.55%
1.96%
Treatment 3.86% ± 9.46%
2.02%
AP v2
Placebo
0.44% ± 10.69%
2.33%
Caffeine
3.88% ± 8.08%
1.85%
Treatment 2.08% ± 14.92%
3.18%
MP v1
Placebo
25.75% ± 84.62%
18.47%
Caffeine
-4.36% ± 28.04%
6.43%
Treatment -11.82% ± 50.05%
10.67%
MP v2
Placebo
-7.99% ± 74.16%
16.18%
Caffeine
-0.06% ± 18.40%
4.22%
Treatment 0.77% ± 24.64%
5.25%

For the digit span memory test score were normalized for percent change in the
same manner as power output and were coded as digit span cumulative 1 visit 1 and 2
(DSCv1 and DSCv2) and digit span total visit 1 and 2 (DSTv1 and DSTv2). For the
digit span the group sizes were slightly different than the power output testing; placebo
N=20, Caffeine N=16 and Treatment N=18. Descriptive statistics for the digit span
memory testing percent change are shown in table 5.
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Table 5
Digit span percent change descriptive statistics
Metric
Group
Mean ± Std. Dev.
DSCv1
Placebo
3.72% ± 15.00%
Caffeine
4.08% ± 18.53%
Treatment 5.78% ± 16.90%
DSCv2
Placebo
6.23% ± 15.19%
Caffeine
3.50% ± 15.96%
Treatment 1.09% ± 20.29%
DSTv1
Placebo
0.57% ± 4.18%
Caffeine
0.85% ± 4.36%
Treatment 1.20% ± 6.77%
DSTv2
Placebo
-0.07% ± 3.97%
Caffeine
-0.11% ± 4.39%
Treatment 1.88% ± 3.99%

Std. Error
3.35%
4.63%
3.98%
3.40%
3.99%
4.78%
0.93%
1.09%
1.60%
0.89%
1.10%
0.94%

Min.
-27.78%
-29.42%
-30.76%
-16.67%
-30.76%
-53.31%
-9.81%
-5.51%
-6.80%
-10.88%
-9.28%
-4.13%

Max.
21.73%
36.85%
28.56%
36.85%
27.27%
29.42%
10.95%
11.92%
25.68%
5.56%
9.03%
10.70%

Analysis of Variance
An ANOVA was run to determine between group differences in the both digit
span and power output percent changes. ANOVA found there was no significant
differences between groups with no main effect in power output percent change as
shown in table 6.
Table 6
ANOVA of power output percent changes
Metrics
F-Value
PPv1
1.289
PPv2
0.297
APv1
1.966
APv2
0.428
MPv1
2.35
MPv2
0.255

P-Value
0.283
0.744
0.149
0.654
0.104
0.799

The minimum power output percent change in visit 1 was trending toward significance
and had the greatest effect size (F= 2.35, P= 0.104) but this was results from the
familiarization and has no significant bearing on the findings of the study. ANOVA
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found similar results for the digit span testing, no significance and no effect as shown in
table 7.
Table 7
ANOVA of digit span percent change
Metrics
F-Value
DSCv1
0.08
DSCv2
0.422
DSTv1
0.069
DSCv2
1.372

P-Value
0.923
0.658
0.933
0.263

Tukey Post Hoc Testing
Post Hoc testing was run using Tukey analysis to find significant differences
between groups (Placebo, Caffeine, and Treatment). Because there were no significant
differences in the ANOVA testing it was highly unlikely there would be a significant
difference found in Post Hoc. All results for the power output percent change are
reported in table 8.
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Table 8
Tukey Post Hoc Testing Peak Power
Metric
Group
Group
PP v1

Placebo
Caffeine
Treatment

PP v2

Placebo
Caffeine
Treatment

AP v1

Placebo
Caffeine
Treatment

AP v2

Placebo
Caffeine
Treatment

MP v1

Placebo
Caffeine
Treatment

MP v2

Placebo
Caffeine
Treatment

Caffeine
Treatment
Placebo
Treatment
Placebo
Caffeine
Caffeine
Treatment
Placebo
Treatment
Placebo
Caffeine
Caffeine
Treatment
Placebo
Treatment
Placebo
Caffeine
Caffeine
Treatment
Placebo
Treatment
Placebo
Caffeine
Caffeine
Treatment
Placebo
Treatment
Placebo
Caffeine
Caffeine
Treatment
Placebo
Treatment
Placebo
Caffeine

Mean Difference ±
Std. Error
-5.29% ± 3.46%
-1.08% ± 3.34%
5.29% ± 3.46%
4.21% ± 3.43%
1.08% ± 3.34%
-4.21% ± 3.43%
-2.03% ± 3.85%
0.86% ± 3.71%
2.03% ± 3.85%
2.88% ± 3.81%
-0.86% ± 3.71%
-2.88% ± 3.81%
-5.19% ± 2.86%
-0.56% ± 2.75%
5.19% ± 2.86%
4.63% ± 2.83%
0.56% ± 2.75%
-4.63% ± 2.83%
-3.44% ± 3.72%
-1.64% ± 3.58%
3.44% ± 3.72%
1.80% ± 3.68%
1.64% ± 3.58%
-1.80% ± 3.68%
30.11% ± 18.89%
37.57% ± 18.20%
-30.11% ± 18.89%
7.46% ± 18.68%
-37.57% ± 18.20%
-7.46% ± 18.68%
-7.93% ± 14.80%
-8.76% ± 14.26%
7.93% ± 14.80%
-0.83% ± 14.64%
8.76% ± 14.26%
0.83% ± 14.64%

P-Value
0.285
0.944
0.285
0.441
0.944
0.441
0.859
0.971
0.859
0.731
0.971
0.731
0.173
0.977
0.173
0.238
0.977
0.238
0.627
0.891
0.627
0.877
0.891
0.877
0.256
0.106
0.256
0.916
0.106
0.916
0.854
0.813
0.854
0.998
0.813
0.998

For the digit span memory test similar results were found, as shown in table 9.
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Table 9
Tuckey Post Hoc
Testing Digit Span
Metrics
Group
DSCv1

Placebo
Caffeine
Treatment

DSCv2

Placebo
Caffeine
Treatment

DSTv1

Placebo
Caffeine
Treatment

DSTv2

Placebo
Caffeine
Treatment

Group
Caffeine
Treatment
Placebo
Treatment
Placebo
Caffeine
Caffeine
Treatment
Placebo
Treatment
Placebo
Caffeine
Caffeine
Treatment
Placebo
Treatment
Placebo
Caffeine
Caffeine
Treatment
Placebo
Treatment
Placebo
Caffeine

Mean difference ±
Std. Error
-0.36% ± 5.61%
-2.06% ± 5.44%
0.36% ± 5.61%
-1.71% ± 5.75%
2.06% ± 5.44%
1.71% ± 5.75%
2.73% ± 5.79%
5.14% ± 5.61%
-2.73% ± 5.79%
2.41% ± 5.93%
-5.14% ± 5.61%
-2.41% ± 5.93%
-0.28% ± 1.75%
-0.63% ± 1.70%
0.28% ± 1.75%
-0.35% ± 1.80%
0.63% ± 1.70%
0.35% ± 1.80%
0.04% ± 1.38%
-1.95% ± 1.33%
-0.04% ± 1.38%
-1.98% ± 1.41%
1.95% ± 1.33%
1.98% ± 1.41%

P-Value
0.998
0.924
0.998
0.953
0.924
0.953
0.885
0.633
0.885
0.913
0.633
0.913
0.986
0.927
0.986
0.979
0.927
0.979
1
0.319
1
0.345
0.319
0.345

Gender differences in percent change
Results were analyzed dividing up the genders which were self-reported on the
health history questionnaire. Sample size for men in power output was N=38 and N=36
for digit span (weight 85.97±12.65 kg. height 1.78±0.074 m.) and the sample size for
women for power output was N=24 and N=18 for digit span (weight 66.54±10.06 kg.
height 1.66±0.062 m.). Each metric (digit span and power output) was analyzed using
ANOVA and reported in the following tables (Tables 10 – 13).
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Table 10
ANOVA of male power output percent changes
Metrics
F-Value
PPv1
2.053
PPv2
0.567
APv1
1.850
APv2
1.375
MPv1
0.789
MPv2
0.916

P-Value
0.144
0.572
0.172
0.266
0.462
0.410

Table 11
ANOVA of female power output percent changes
Metrics
F-Value
P-Value
PPv1
0.079
0.924
PPv2
0.234
0.794
APv1
0.310
0.737
APv2
0.043
0.958
MPv1
1.626
0.221
MPv2
1.147
0.337

Table 12
ANOVA of male digit span percent change
Metrics
F-Value
P-Value
DSCv1
0.019
0.981
DSCv2
0.206
0.815
DSTv1
0.485
0.620
DSCv2
0.880
0.424

Table 13
ANOVA of female digit span percent change
Metrics
F-Value
P-Value
DSCv1
0.426
0.661
DSCv2
0.606
0.558
DSTv1
0.259
0.775
DSCv2
0.338
0.718

As shown in tables 10- 13 there was no significant differences within groups or
between groups with genders separated.
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Upon further investigation of the digit span memory test visit 1 pre-exhaustion
scores and post-exhaustion were compared to the visit 2 pre and post using ANOVA
with LSD and Tukey Post Hoc multiple comparisons. The scores were not based on
percent change but what their percent of success was in DSC and DST. Descriptive
statistics, ANOVA and Post Hoc multiple comparisons were reported in tables 14, 15
and 16.
Table 14
Post exhaustion digit span total score descriptive statistics
Metric
Group
N
Mean ± Std. Dev.
Std. Error
V1 DST Placebo
20
0.937 ± 0.062
0.014
Caffeine
17
0.938 ± 0.044
0.010
Treatment 19
0.937 ± 0.067
0.015
V2 DST Placebo
20
0.959 ± 0.032
0.007
Caffeine
17
0.948 ± 0.041
0.009
Treatment 19
0.933 ± 0.045
0.010

Table 15
ANOVA Post exhaustion Digit Span total
Metric
F-Value P-Value
V1 DST
0.001
0.999
V2 DST
2.047
0.139
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Table 16
LSD multiple comparisons
Group
Group

Metric

Mean
difference
V1 DST
Placebo
Caffeine
-0.000
Treatment -0.000
Caffeine
Placebo
0.000
Treatment 0.000
Treatment Placebo
0.000
Caffeine
-0.000
V2 DST
Placebo
Caffeine
0.011
Treatment .026*
Caffeine
Placebo
-0.011
Treatment 0.015
Treatment Placebo
-.026*
Caffeine
-0.015
* The mean difference is significant at the 0.05 level

Std.
Error
0.019
0.019
0.019
0.019
0.019
0.019
0.013
0.012
0.013
0.013
0.012
0.013

P-Value
0.963
0.982
0.963
0.981
0.982
0.981
0.424
0.049
0.424
0.26
0.049
0.26

As seen in table 16, significance differences were found between groups at alpha
level 0.049. The difference found was between the treatment and placebo groups based
on the mean difference score of -0.026 subjects seemed to do better with the simple carb
supplement in post exhaustion compared to the Supplement provided. Though found
significant, it does not hold much bearing, the finding is likely a Type 1 Error (False
Positive).
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Chapter 5

Conclusion

The results of this study indicate that acute ingestion of 200 micrograms of HupA with 600 milligrams of Alpha-GPC had no effect on cognitive or physical
performance in a healthy, recreationally active population. Further-more the results
suggest that after exhaustion the combination of Hup-A and Alpha-GPC may decrease
cognitive performance. This does not line up with the current body of knowledge about
the combination of Hup-A and Alpha-GPC, because this is the first study of its kind to
look at a combination at this dose in a controlled environment with healthy participants.
As stated by Jay Hoffman, past investigators have suggested that cholinergic
supplementation may be beneficial for exercise, particularly exhaustive exercise, based
on the belief that exercise lowers levels of acetylcholine concentrations resulting in
fatigue and decrease in performance (Hoffman et. al., 2010). Given that information, a
logical assumption would be that increasing the amount of acetylcholine in the system
would mitigate the effects of fatigue. But Spector and other investigators found that
choline supplementation did not improve performance in fatiguing cycling (Spector,
Jackman, Sabounjian, Sakkas, Landers, & Willis, 1995). These assumptions are widely
accepted across supplement companies and the same logic is used in nutrition blogs or
advertisements for pre-workout and nootropic supplements. Companies are making
these claims based on untested assumption without support in the research. This is a
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common practice in supplement companies to sell new lines of product to fitness
enthusiasts (Jagim, et. al., 2016).
One goal of this study was to put the supplement combination of Alpha-GPC
and Hup-A to the test and see if there was an ergogenic effect based on the assumptions
mentioned earlier. Based on the results from this study there was no effect on
performance. The current body of research for these two supplements are done on an
individual basis and in most cases are performed on subjects with Alzheimer’s or
Dementia (Wang, et. al., 2009, & Barbagallo, et. al., 1994). Barbagallo et. al. found that
the use of Alpha-GPC over a period of 28 days in patients with recent stroke or transient
ischemic attacks helped psychological recovery. Similarly, a meta-analysis by Wang et.
al. on the effects and efficacy of Hup-A as a treatment for Alzheimer’s disease. Wang
found that after an 8-24-week period of ingesting 300-500 micrograms of Hup-A orally
significantly improved the scores of patients with Alzheimer’s disease. The tests they
used were the Mini-mental state examination and the Activities of daily living scale.
The Mini-mental state examination is brief test to screen for Dementia including
questions on orientation, attention, recall and language (Galea & Woodard, 2005). As
seen in these two studies each supplement has been shown to be safe and effective in
increasing cognitive ability in those with neurodegenerative diseases. These studies
demonstrate there is a use for these supplements in those specific populations but there
is little other evidence to support the claims made by companies that they are beneficial
for a healthy population. Because of this gap in literature we investigators felt it was
necessary to see the potential in a healthy population. Both the mini-mental state exam
and the activities of daily living scale are self-reported questionnaire. For this study the
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investigators found it important that the treatment of Alpha-GPC and Hup-A be tested
using quantifiable results to find if there is an actual change and not the perception of
change. Another difference is the acute supplementation versus the chronic
supplementation model. An acute model was chosen to more accurately represent how
pre-workout supplements are taken by the recreationally trained population (30-60
minutes/upon arrival). The previous literature only shows the changes in ill populations
and none of the testing in Hup-A is done using a demonstrable performance-based test,
they are all self-reported tests based on self-perception which is not always indicative of
reality.
The use of healthy recreationally trained subjects was purposeful because these
are predominantly the ones being targeted by the supplement companies to buy their
products. As previously mentioned, these companies are not required to show empirical
evidence to support their claim that they work (Martinez, Campbell, Franek, Buchanan,
& Colquhoun, 2016). Even without the proper support for their claim they shamelessly
market their products. Take this article by Cellucor (a supplement company) for
example;
“Studies have also suggested that Huperzine-A can boost your mental energy.
Taken as a part of your pre-workout supplement, you may have more mental energy and
a better ability to learn and remember new exercises.”
“As a pre-workout supplement, Alpha GPC can help to boost your mental
energy.”
“It also helps with athletic performance. A study published in Journal of the
International Society of Sports Nutrition demonstrated that Alpha GPC supplementation
resulted in elevated levels of lower body strength output, and researchers confirmed it
can be useful in promoting overall speed and power.”
“Finally, Alpha GPC has been said to pair extremely well with other nootropics,
such as Huperzine A and caffeine, resulting in enhanced benefits.”
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The only cited research specific to Alpha-GPC or Hup-A in this article references to the
previously mentioned study by Bellar and colleagues stating it increases lower limb
isometric strength by an average of 22.2 lbs. 6 days of loading at 600 mg. a day (Bellar,
2015). The supplement they sell using this article only contains 200 mg preserving. This
is a classic example of supplement companies making false claims to sell a product.
Another comparison performed in the current study was comparing the effects
of the Alpha-GPC/Hup-A to caffeine dosed at 5 milligrams per-kilogram of
bodyweight. This dose was chosen because it was found to be efficacious in improving
both physical and cognitive performance in healthy subjects (Pasman et. al., 1995,
Davis and Green, 2009, Vanakoski et. al., 1998). Based on the results there was no
significant difference between groups at any level. The results of this study found that
neither Alpha-GPC/Hup-A or Caffeine influenced performance compared to placebo
which is not supported by the current research. This has led the investigators to believe
there are some design flaws in the method used to test the supplements.
The study used a randomized double-blind procedure to make sure there was no
influence on the subjects from the testers. Optimally, it would not be three separate
groups, but a randomized cross-over design where each subject was given all three
treatments. This would control better for inter-subject variations because each subjects’
results would be compared against themselves. Other issues with the design was the
freedom given to subjects on the start time for their Wingate bike sprint. Subjects were
given the option to start as early as 1 minute and 30 seconds or as late as 5 minutes after
pedaling at 60-100 rpm. The variation in the warm-up time could have led to the
consistency issues experienced between visits and between subjects. Another issue is
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unfamiliarity with the equipment causing issues with executing the test properly even
under instruction.
Gender specific comparisons were analyzed to determine if there was a possible
gender specific effect. The result suggests there is no gender difference between groups
implying one gender reacts more to the substances than another. Currently there is no
published data looking at the differences between genders in these supplements. The
cause of this may be due to what is known as survivorship bias in research (Brown &
Goetzmann, 2018). This is based on the idea that in research many times only the
studies that found that something worked are published. So, if there was a study that
found that the supplement combination didn’t work it may not have been published due
to this bias.
Future Research
In the event future investigators try to recreate the current study they should take
into consideration some of the issues that the primary investigators encountered. One
issue with a two-visit test was the natural learning effect that subjects had when
performing these new tasks. In many cases the subject would do better in the second
Wingate sprint than in the first one. Based on the individuals experience and with
performing Wingate’s investigators believe that from pre to post the subjects had a
better understanding of how to perform the testing. So, even after being put in a state of
exhaustion, subjects would produce higher peak power. To control for this issue, if a
subject comes in for the first test and scores higher in the post testing than the pretesting, they should have to come in for another familiarization test. Another issue is
proper warm-ups. Investigators should have used the standard 5 minutes at 60-100 rpm
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warm up to control for variations between subject visits. Lastly, in several studies
previously mentioned the supplements were given over a span of 28 days or 8 weeks.
Given this information future investigators should consider examining the effects
Alpha-GPC and Hup-A after a loading period.
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Consent to Participate in a Research Study
Effects of Alpha-GPC and Huperzine-A on Short
Term
Memory, Anaerobic Power Output, Post Exhaustion
compared to Caffeine and placebo in Healthy
College Age Students

2422
6 /11/19-5/1/ 20

Key Information
You are being invited to participate in a research study. This document includes important
information you should know about the study. Before providing your consent to participate,
please read this entire document and ask any questions you have.

Do I have to participate?
If you decide to take part in the study, it should be because you really want to volunteer. You
will not lose any benefits or rights you would normally have if you choose not to volunteer.
You can stop at any time during the study and still keep the benefits and rights you had before
volunteering. If you decide to participate, you will be one of about 60 people in the study.

What is the purpose of the study?
The purpose of the study is to determine if the two supplements (Alpha-GPC and Huperzine-A)
will be more effective in improving mental and physical performance compared to a placebo or
caffeine. Another purpose of this study is to determine if the two supplements will increase
performance once you are tired after doing multiple exercises. You have been selected to
participate because you are a healthy person between the ages of 18-40 years old and with the
proper amount of training history (2 or more years), and are not pregnant.

Where is the study going to take place and how long will it last?
The research procedures will be conducted at the Moberly building on Eastern Kentucky
University’s campus. You will need to come to Moberly 223 a total of 2 times over the period
of 2 weeks during the study. Each visit will take approximately 1 hour to 1 hour and 15
minutes. The total amount of time you will be asked to volunteer for this study is 2-3 hours
over the next 14 days.

What will I be asked to do?
For the first visit, you will be required to complete a survey about your current caffeine usage
and a health history questionnaire. If you are a female participant, you will be required to visit
the student health center to take a pregnancy test to verify you are not currently pregnant. A
note from the student health center must be provided to the research team prior to
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participating in the testing procedures. Once the survey is completed, you will be asked to
perform a simple body composition test to determine body fat and fat free mass. This will
require you to stand still for one minute while standing on an electronic scale. Lastly, you will
have your blood pressure and resting heart rate taken by an automatic blood pressure cuff.
After all paper work and body composition testing is finished, you will be asked to perform a
memory test. For the test, you will be required to watch a computer screen that will show a
series of numbers to you. Once all the numbers in the sequence have been displayed, you will
be asked to type the digits you saw in order, to the best of your ability. The sequences will
increase from 2 to 10 digits.
After the memory test has been completed, you will then sit on a stationary bike and be asked
to pedal for 1 minute at a medium pace. After 1 minute, you will sprint for 10 seconds against
no resistance then return to a medium pace for 1 minute before working up to a 30 second all
out sprint against a brake weight of 7.5% of your body weight. You will be allowed a period to
pedal as a cool down for three minutes before moving on to the next step of testing which will
include 3 different exercises. The exercises will include: 1 minute of body weight squats, 1
minute of push-ups (from toes or knees), and 1 minute of sit ups. You will be asked to perform
as many repetitions of each exercise as you can during each minute. Once all 3 exercises are
finished, you will rest quietly for 7-10 minutes and can drink water if needed. After the rest
period, you will repeat the memory test and the bike test.
For the second visit, you will be required to drink one of the following: the combination of both
AlphaGPC and Huperzine-A, caffeine, or placebo and then sit quietly for 30 minutes while the
drink digests. Once the digestion period is over, you will be asked to complete the same testing
process as the first visit. You have an equal chance of being assigned to each drink.

Are there reasons why I should not take part in this study?
You should not participate in this study if you are under the age of 18 or over 40 years old,
have chronically high blood pressure (blood pressure greater than 140/90), a high resting heart
rate (beats per minute greater than 100), a history of metabolic (diabetes), cardiovascular
(heart disease), or respiratory disease (asthma). If you are or could be pregnant. Also, if
you have orthopedic issues (joint, muscle, or ligament pain), or mobility limitations, you may
not want to participate. Lastly, if you have allergies to the any of the supplements you may be
taking in this study, you will want to refrain from participation.

What are the possible risks and discomforts?
Possible risks and discomforts that may occur are as follows.
•
Bike test may cause muscle fatigue, heavy breathing, sweating, and mild
nausea.
•
Exercises may cause muscle fatigue, heavy breathing, sweating, muscle
soreness, and mild nausea.
•
Supplements may cause increased nervousness, anxiety, mild nausea, and a
slim chance of diarrhea.
These discomforts may only last 1-2 minutes or as long as 15 minutes based on each
individual. Muscle soreness after strenuous exercise is a common side effect but may not occur
until 1-2 days after testing is complete. This discomfort (if any) will likely not last longer than 3
days. If you have any further questions/concerns, please contact the research team, contact
information is located on page 3.
You may, however, experience a previously unknown risk or side effect.

What are the benefits of taking part in this study?
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You are not likely to get any personal benefit from taking part in this study. Your participation
is expected to provide benefits to others by finding if the combination of the previously
mentioned supplements are as effective or more effective than caffeine.

If I don’t take part in this study, are there other choices?
If you do not want to be in the study, there are no other choices except to not take part in the
study.
Now that you have some key information about the study, please continue reading if you are
interested in participating. Other important details about the study are provided below.

Other Important Details
Who is doing the study?
The person in charge of this study is John Isaacs, a graduate assistant in the Exercise and
Sports Science Department at Eastern Kentucky University. Dr. Michael Lane, Dr. Aaron
Sciascia, and Dr. Donald Varakin will be advising him. There may be other people on the
research team assisting at different times during the study.

What will it cost me to participate?
There are no costs associated with taking part in this study.

Will I receive any payment or rewards for taking part in the study?
You will not receive any payment or reward for taking part in this study.

Who will see the information I give?
Your information will be combined with information from other people taking part in the study.
When we write up the study to share it with other researchers, we will write about this
combined information. You will not be identified in these written materials.
All data will be kept confidential and you will not be identifiable. All records will be kept under
lock and key. Only those researchers listed above will have access to identifiable information
and data results.

Can my taking part in the study end early?
If you decide to take part in the study, you still have the right to decide at any time that you no
longer want to participate. You will not be treated differently if you decide to stop taking part
in the study.
The individuals conducting the study may need to end your participation in the study. They
may do this if you are not able to follow the directions they give you, if they find that your
being in the study is more risk than benefit to you, or if the University or agency funding the
study decides to stop the study early for a variety of reasons.

What happens if I get hurt or sick during the study?
If you believe you are hurt or get sick because of something that is done during the study, you
should call John Isaacs at 502-320-3371 or Dr. Michael Lane at 859-622-1890 immediately. It
is important for you to understand that Eastern Kentucky University will not pay for the cost of
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any care or treatment that might be necessary because you get hurt or sick while taking part in
this study. Also, Eastern Kentucky University will not pay for any wages you may lose if you are
harmed by this study. These costs will be your responsibility.
Usually, medical costs that result from research-related harm cannot be included as regular
medical costs. Therefore, the costs related to your care and treatment because of something
that is done during the study will be your responsibility. You should ask your insurer if you
have any questions about your insurer’s willingness to pay under these circumstances.

What else do I need to know?
You will be told if any new information is learned which may affect your condition or influence
your willingness to continue taking part in this study.
We will give you a copy of this consent form to take with you.

Consent
Before you decide whether to accept this invitation to take part in the study, please ask any
questions that come to mind now. Later, if you have questions about the study, you can
contact the investigator,
John Isaacs at 502-320-3371 John_isaacs38@mymail.eku.edu or Dr. Michael Lane at
Michael.lane@eku.edu (859-622-1890). If you have any questions about your rights as a
research volunteer, you can contact the staff in the Division of Sponsored Programs at Eastern
Kentucky University at 859-622-3636.
If you would like to participate, please read the statement below, sign, and print your name.

I am at least 18 years of age, have thoroughly read this document, understand its
contents, have been given an opportunity to have my questions answered, and voluntarily
agree to participate in this research study.

Signature of person agreeing to take part in the study

Printed name of person taking part in the study

Name of person providing information to
subject
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Appendix B: Caffeine Survey
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Effects of Alpha-GPC and Huperzine-A on Short Term Memory, Anaerobic Power Output, Post
Exhaustion compared to Caffeine and placebo in Healthy College Age Students
Caffeine Consumption survey
Name___________________
Date_________

Age______

Weight_________

Scale of 1 – 10 (1=not at all, 10=can’t be without). How much do you depend on caffeine on a
daily basis to function properly? ________
What form of caffeine do you most often consume?
_____________________________________________________________________________
_____________________________________________________________________________
________________
Give a rough estimate of how many milligrams (Mg) of caffeine you consume daily (Example 1
cup of coffee = roughly 90-100 mg of caffeine) _________
Weekly_____________
Intake guidelines chart
Drinks/Foods

Volume

Caffeine content mean &
range
85 (65-135)
60 (35-100)
65 (35-105)
3 (1-5)
32 (20-45)
20 (10-50)
4 (2-7)
39 (30-48)
41 (26-57)

Filter coffee
125 ml (4 Fl. Oz. cup)
Espresso
30 ml (1 shot)
Soluble Instant Coffee
125 ml (4 Fl. Oz. cup)
Decaffeinated
125 ml (4 Fl. Oz. cup)
Tea
150 ml (5 Fl. Oz cup)
Iced Tea
330 ml (11 Fl. Oz. cup)
Hot chocolate
150 ml (5 Fl. Oz. cup)
Caffeinated soft drinks
330 ml (11 Fl. Oz. cup)
Sugar-free Caffeinated soft
330 ml (11 Fl. Oz. cup)
drinks
Energy Drinks
330 ml (11 Fl. Oz. cup)
80 (70-120)
Pre-workout
1 powder scoop
300 (200-400)
Chocolate bar
30 g (1 Oz.)
20 (5-36)
Milk Chocolate
30 g (1 Oz.)
6 (1-15)
Dark Chocolate
30 g (1 Oz.)
60 (20-120)
Source (https://www.coffeeandhealth.org/topic-overview/sources-of-caffeine/)
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Appendix C: Recruitment Script
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Recruitment script.
Thank you for allowing me to come speak to your class about the current research I
will be conducting in the exercise physiology lab here at Eastern Kentucky University.
The current study is “Effects of Alpha-GPC and Huperzine-A on Short Term Memory, Anaerobic
Power Output, Post Exhaustion compared to Caffeine and placebo in Healthy College Age
Students”. In this study you will be asked to come to the exercise physiology lab for 2, 1-hour
long visits. In each visit you will be asked to perform a digit span memory test, Wingate
anaerobic power test, exhaustive protocol, and then repeat the digit span and Wingate tests.
In the first visit you will be divided randomly into either a caffeine group, placebo
group, or treatment group. The group you are assigned to will be blinded to both the
researcher conducting the tests and you. Each supplement will be in specific doses to provide a
specific ergogenic effect (caffeine 5mg/kg, Alpha-GPC 600mg and Huperzine-A 200mcg). All
doses have been tested for safety and been shown to be safe for use in acute dosing.
All subjects must have a least 2 years’ experience in some form of physical training and be
between 18-40 years of age. Sign ups are with me and you can contact me at
John_isaacs38@mymail.eku.edu if you are interested.
Thank you,
John Isaacs
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Effects of Alpha-GPC and Huperzine-A on Short Term Memory, Anaerobic Power
Output, Post Exhaustion compared to Caffeine and placebo in Healthy College Age
Students
Primary investigator: John Isaacs. Sub-Investigators: Michael Lane
Familiarization
Subject Name______________________(optional)
Date_____________
Subject number______

Height_______

Weight________

Body

Comp______
Hours of sleep last night_______
Digit span score Pre-test______________
Wingate Pre-test-Peak________

Average________

Minimum_________
# of sit ups__________

# of push up_________

# of squats __________

Digit span score Post-Test___________
Wingate Post-Test- Peak____________

Average_________

Minimum___________
_____________________________________________________________________________
________
Visit 2
Date_______________
Digit span score Pre-test______________
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Wingate Pre-test-Peak________

Average________

Minimum_________
# of sit ups__________

# of push up_________

# of squats __________

Digit span score Post-Test___________
Wingate Post-Test- Peak____________

Average_________

Minimum___________
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